Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that they have entered a major strategic alliance in which Genzy
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
Genzyme Corporation (NASDAQ: GENZ) today reported financial results for the full year and fourth quarter of 2007 and provided an outlook for continued strong growth in 2008 and beyond.
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
Genzyme Corp. (Nasdaq: GENZ) announced the U.S. launch of the phosphate binder Renvela® (sevelamer carbonate) for dialysis patients, as well as significant progress in its international efforts to se
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
Genzyme Corp. (Nasdaq: GENZ) announced the withdrawal of the European application to extend the Evoltra® (clofarabine) product label to include the treatment of elderly patients with acute myeloid le
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
Genzyme Corp. (Nasdaq: GENZ) announced today that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion a
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
Genzyme Corporation (NASDAQ: GENZ) reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, an
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
Genzyme Corp. (NASDAQ: GENZ) reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compo
read more » Discuss Add this link to...Bury Add to:
| Bookmarks